BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Freedman MS, Devonshire V, Duquette P, Giacomini PS, Giuliani F, Levin MC, Montalban X, Morrow SA, Oh J, Rotstein D, Yeh EA. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci 2020;47:437-55. [DOI: 10.1017/cjn.2020.66] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Hartung HP, Meuth SG, Miller DM, Comi G. Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis. Curr Opin Neurol 2021;34:598-603. [PMID: 33990101 DOI: 10.1097/WCO.0000000000000960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Saposnik G, Andhavarapu S, Fernández Ó, Kim HJ, Wiendl H, Foss M, Zuo F, Havrdová EK, Celius EG, Caceres F, Magyari M, Bermel R, Costa A, Terzaghi M, Kalincik T, Popescu V, Amato MP, Montalban X, Oh J. Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists. Mult Scler Relat Disord 2022;57:103389. [PMID: 35158479 DOI: 10.1016/j.msard.2021.103389] [Reference Citation Analysis]
3 Inojosa H, Proschmann U, Akgün K, Ziemssen T. The need for a strategic therapeutic approach: multiple sclerosis in check. Therapeutic Advances in Chronic Disease 2022;13:204062232110630. [DOI: 10.1177/20406223211063032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Thebault S, Booth RA, Rush CA, MacLean H, Freedman MS. Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation. Front Neurosci 2021;15:654942. [PMID: 33841093 DOI: 10.3389/fnins.2021.654942] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chu L, Casserly C, Rosehart H, Morrow SA. Is there a multiple sclerosis personality? Personality characteristics in newly diagnosed multiple sclerosis and association with mood and cognition. Journal of the Neurological Sciences 2022;434:120145. [DOI: 10.1016/j.jns.2022.120145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Weinstock-Guttman B, Bermel R, Cutter G, Freedman MS, Leist TP, Ma X, Kile D, Musch B, Reder AT, Wolinsky JS. Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Mult Scler 2021;:13524585211035740. [PMID: 34382875 DOI: 10.1177/13524585211035740] [Reference Citation Analysis]
7 Ford CC, Cohen JA, Goodman AD, Lindsey JW, Lisak RP, Luzzio C, Pruitt A, Rose J, Rus H, Wolinsky JS, Kadosh SE, Bernstein-Hanlon E, Stark Y, Alexander JK. Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study. Mult Scler 2022;:13524585221094239. [PMID: 35768939 DOI: 10.1177/13524585221094239] [Reference Citation Analysis]
8 Fragoso YD, Branco LP, de Carvalho VM. Pregnancy and Family Planning Considerations in Multiple Sclerosis. Curr Obstet Gynecol Rep. [DOI: 10.1007/s13669-022-00329-4] [Reference Citation Analysis]
9 Muñoz Ú, Sebal C, Escudero E, Urcelay E, Arroyo R, García-Martínez MA, Quintana FJ, Álvarez-Lafuente R, Sádaba MC. Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-β. Sci Rep 2022;12:13357. [PMID: 35922641 DOI: 10.1038/s41598-022-16218-y] [Reference Citation Analysis]
10 Lees S, Dicker M, Ku JE, Chaganti V, Mew-Sum M, Wang N, Smith A, Oldmeadow C, Goon WL, Bevan M, Lang D, Hinwood M. Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis. BMJ Open 2021;11:e051509. [PMID: 34728450 DOI: 10.1136/bmjopen-2021-051509] [Reference Citation Analysis]
11 Morrow SA, Clift F, Devonshire V, Lapointe E, Schneider R, Stefanelli M, Vosoughi R. Use of natalizumab in persons with multiple sclerosis: 2022 update. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103995] [Reference Citation Analysis]
12 Landrigan J, Bessenyei K, Leitner D, Yakovenko I, Fisk JD, Prentice JL. A systematic review of the effects of cannabis on cognition in people with multiple sclerosis. Multiple Sclerosis and Related Disorders 2022;57:103338. [DOI: 10.1016/j.msard.2021.103338] [Reference Citation Analysis]
13 Caparó-Zamalloa C, Velásquez-Rimachi V, Mori N, Dueñas-Pacheco WI, Huerta-Rosario A, Farroñay-García C, Molina RA, Alva-Díaz C. Clinical Pathway for the Diagnosis and Management of Patients With Relapsing-Remitting Multiple Sclerosis: A First Proposal for the Peruvian Population. Front Neurol 2021;12:667398. [PMID: 34744956 DOI: 10.3389/fneur.2021.667398] [Reference Citation Analysis]
14 Oh J, Bar-Or A. Emerging therapies to target CNS pathophysiology in multiple sclerosis. Nat Rev Neurol 2022. [PMID: 35697862 DOI: 10.1038/s41582-022-00675-0] [Reference Citation Analysis]
15 Parks NE. Navigating the TOR of Multiple Sclerosis. Can J Neurol Sci 2020;47:435-6. [PMID: 32326985 DOI: 10.1017/cjn.2020.76] [Reference Citation Analysis]
16 Bose G, Freedman MS. Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis. J Neurol Sci 2021;421:117324. [PMID: 33497951 DOI: 10.1016/j.jns.2021.117324] [Reference Citation Analysis]
17 Yang JH, Rempe T, Whitmire N, Dunn-pirio A, Graves JS. Therapeutic Advances in Multiple Sclerosis. Front Neurol 2022;13:824926. [DOI: 10.3389/fneur.2022.824926] [Reference Citation Analysis]
18 Sadovnick D, Criscuoli M, Yee I, Carruthers R, Schabas A, Smyth P. The road to conception for women with multiple sclerosis. Mult Scler J Exp Transl Clin 2021;7:20552173211032313. [PMID: 34350028 DOI: 10.1177/20552173211032313] [Reference Citation Analysis]
19 Guler S. Factors determining the treatment ineffectiveness in multiple sclerosis. Neurol Res 2021;:1-9. [PMID: 34396921 DOI: 10.1080/01616412.2021.1967680] [Reference Citation Analysis]
20 Vermersch P, Oreja-Guevara C, Siva A, Van Wijmeersch B, Wiendl H, Wuerfel J, Buffels R, Kadner K, Kuenzel T, Comi G; CASTING Investigators. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial. Eur J Neurol 2021. [PMID: 34748672 DOI: 10.1111/ene.15171] [Reference Citation Analysis]